Armata Pharmaceuticals
ARMP
20 hedge funds and large institutions have $6.61M invested in Armata Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
18% more funds holding
Funds holding: 17 → 20 (+3)
0.48% less ownership
Funds ownership: 4.88% → 4.4% (-0.48%)
9% less capital invested
Capital invested by funds: $7.25M → $6.61M (-$635K)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$99.3K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$61.6K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$53.3K |
| 4 |
SWM
SeaCrest Wealth Management
Purchase,
New York
|
+$16.4K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$3.61K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$66K |
| 2 |
Renaissance Technologies
New York
|
-$15.9K |
| 3 |
BlackRock
New York
|
-$6.13K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$3.19K |
| 5 |
SF
Synovus Financial
Columbus,
Georgia
|
-$676 |
ARMP Hedge Fund Activity: Q1 2022 in Review
20 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Armata Pharmaceuticals (ARMP) for Q1 2022, worth a combined $6.61M — down 8.8% from $7.25M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ARMP positions and 1 closed out — a net gain of 3 holders — while 5 added to existing stakes and 6 trimmed.
The largest buyer was Northern Trust, opening a new position worth an estimated $99.3K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $66K sold.
- 20 institutional investors held Armata Pharmaceuticals (ARMP) as of Q1 2022, up from 17 in Q4 2021.
- Funds reported $6.61M of Armata Pharmaceuticals stock for Q1 2022, down 8.8% quarter-over-quarter.
- 4 funds opened new Armata Pharmaceuticals positions in Q1 2022 and 1 closed out, a net change of +3 holders.
- The largest Armata Pharmaceuticals buyer in Q1 2022 was Northern Trust, an estimated $99.3K added.
- The largest Armata Pharmaceuticals seller in Q1 2022 was Susquehanna International Group, an estimated $66K sold.
Based on aggregated 13F filings for Q1 2022.